Glaxosmithkline Share News (GSK)

BUZZ-India's GlaxoSmithKline Pharma hits record high on hopes of good results, delisting

** India's GlaxoSmithKline Pharmaceuticals jumps as much as 11.8 pct to record high ** Heading towards biggest daily gain since Dec 2013 ** Shares surge on hopes of good results and potential delisting by parent company - analysts ** Indian market regulator Securities and Exchan

First GSK Ebola vaccine shipment due to arrive in Liberia

By Kate Kelland LONDON, Jan 23 (Reuters) - The first batch of GlaxoSmithKline's experimental Ebola vaccine has been shipped to West Africa and is expected to arrive in Liberia later on Friday, the British drugmaker said. The shipment, of an initial 300 vials of the vaccine, will be th

UPDATE 1-US health officials say Ebola treatment trial to start soon in Liberia

(Adds details on trials) Jan 22 (Reuters) - U.S. health officials said on Thursday that they are planning to start larger, decisive clinical trials in Liberia in the next two weeks to determine if two new Ebola treatments under development are safe and effective. One of the treatments

US health officials say Ebola treatment trial to start soon in Liberia

Jan 22 (Reuters) - U.S. health officials said on Thursday that they are planning to conduct larger phase 2/3 clinical trials starting in the next two weeks in Liberia to determine if an Ebola treatment being developed by GlaxoSmithKline and another by Newlink Genetics with Merck & Co are safe and

Vaccines group seeks $7.5 bln as disease fight reaches peak

By Ben Hirschler DAVOS, Switzerland, Jan 22 (Reuters) - The GAVI global vaccines alliance is seeking to raise $7.5 billion at a funding conference in Berlin next week, as its battle to prevent infectious diseases in millions of children reaches an expected peak. The non-profit organis

Incoming Takeda CEO ready to do deals after refocusing drug company

* Japanese drugmaker in better position to be active * Follows refocusing of group on three growth areas * Priorities are oncology, gastrointestinal, emerging markets By Ben Hirschler DAVOS, Switzerland, Jan 21 (Reuters) - Takeda Pharmaceutical , Japan's largest drugmaker,

MSF slams expensive vaccines, urges GSK and Pfizer to cut prices

By Kate Kelland, Health and Science Correspondent LONDON, Jan 20 (Reuters) - the international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries. In a report on v

Sunday share tips: Mitie, UK Mail, Vodafone

Mitie's shares have fallen but not as fast as those of outsourcing rivals such as Serco and Balfour Beatty, Danny Fortson pointed out in the Sunday Times. Matthew Earl, a former City analyst who writes a blog, criticised Mitie for buying companies to compensate for its own slow progress and for the

GSK's nicotine patches and gum feel the heat from e-cigarettes

By Kate Kelland LONDON, Jan 16 (Reuters) - GlaxoSmithKline is feeling the heat from the rapid growth in electronic cigarettes, with enthusiasm for the nicotine delivery devices dampening sales of the British drugmaker's patches and gum, its chief executive said. In an interview with R

UK BROKER RATINGS: SocGen Upgrades BT To Buy From Hold

Researchers find clues on how melanoma resists effective treatments

By Bill Berkrot Jan 15 (Reuters) - Researchers believe they have discovered a mechanism by which tumors eventually evade effective combination treatments for melanoma, providing clues that could lead to longer-lasting therapies for the deadliest of skin cancers. The two-year study, le

UK BROKER RATINGS: Goldman Adds BHP Billiton To Conviction Buy List

UPDATE 1-FDA places Arrowhead Hep B drug on partial hold, shares plunge

(Adds details, background, updates share movement) Jan 12 (Reuters) - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.

BUZZ-SkyePharma: disappointing sales hit shares

** SkyePharma dives to lowest levels in more than 4 mths on lower-than-expected GlaxoSmithKline Q3 2014 sales of Relvar/Breo Ellipta and Anoro Ellipta, which both use SkyePharma licensed technology [ID: ** Stock, which has had great run over the past year, rising around 200 pct, down 16.5 p

Skyepharma To Meet Expectations But Glaxo Royalties Slower